Stock Scorecard
Stock Summary for Ligand Pharmaceuticals Inc - Class B (LGND) - $139.10 as of 7/18/2025 8:35:57 PM EST
Total Score
7 out of 30
Safety Score
41 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for LGND
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for LGND
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for LGND
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for LGND
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for LGND (41 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 0 |
| Book Value (Max of 10) | 8 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for LGND
Financial Details for LGND
Company Overview |
|
|---|---|
| Ticker | LGND |
| Company Name | Ligand Pharmaceuticals Inc - Class B |
| Country | USA |
| Description | Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | 8/11/2025 |
Stock Price History |
|
| Last Day Price | 139.10 |
| Price 4 Years Ago | 154.46 |
| Last Day Price Updated | 7/18/2025 8:35:57 PM EST |
| Last Day Volume | 347,058 |
| Average Daily Volume | 151,674 |
| 52-Week High | 130.94 |
| 52-Week Low | 90.29 |
| Last Price to 52 Week Low | 54.06% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.12 |
| Sector PE | 40.31 |
| 5-Year Average PE | 31.12 |
| Free Cash Flow Ratio | 55.64 |
| Industry Free Cash Flow Ratio | 18.49 |
| Sector Free Cash Flow Ratio | 32.75 |
| Current Ratio Most Recent Quarter | 5.27 |
| Total Cash Per Share | 2.50 |
| Book Value Per Share Most Recent Quarter | 41.27 |
| Price to Book Ratio | 3.02 |
| Industry Price to Book Ratio | 34.63 |
| Sector Price to Book Ratio | 31.07 |
| Price to Sales Ratio Twelve Trailing Months | 13.49 |
| Industry Price to Sales Ratio Twelve Trailing Months | 140.85 |
| Sector Price to Sales Ratio Twelve Trailing Months | 40.56 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 19,191,000 |
| Market Capitalization | 2,669,468,100 |
| Institutional Ownership | 99.82% |
Dividends |
|
| Ex-Dividend Date | 7/2/2010 |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.4560 |
| Total Years Dividend Increasing | 0 |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | -96.96% |
| 3-Year Dividend Growth Rate Percentage | -96.96% |
| 5-Year Dividend Growth Rate Percentage | -96.96% |
| All-Time Dividend Growth Rate Percentage | -96.96% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 103.20% |
| Annual Earnings Growth | -107.73% |
| Reported EPS 12 Trailing Months | -7.28 |
| Reported EPS Past Year | 1.33 |
| Reported EPS Prior Year | 5.71 |
| Net Income Twelve Trailing Months | -132,622,000 |
| Net Income Past Year | -4,032,000 |
| Net Income Prior Year | 52,154,000 |
| Quarterly Revenue Growth YOY | 46.30% |
| 5-Year Revenue Growth | 6.80% |
| Operating Margin Twelve Trailing Months | -80.90% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 47,989,000 |
| Total Cash Past Year | 72,307,000 |
| Total Cash Prior Year | 22,954,000 |
| Net Cash Position Most Recent Quarter | -28,801,000 |
| Net Cash Position Past Year | -4,388,000 |
| Long Term Debt Past Year | 76,695,000 |
| Long Term Debt Prior Year | 76,695,000 |
| Total Debt Most Recent Quarter | 76,790,000 |
| Equity to Debt Ratio Past Year | 0.92 |
| Equity to Debt Ratio Most Recent Quarter | 0.91 |
| Total Stockholder Equity Past Year | 830,439,000 |
| Total Stockholder Equity Prior Year | 700,913,000 |
| Total Stockholder Equity Most Recent Quarter | 795,534,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 35,507,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 1.85 |
| Free Cash Flow Past Year | 95,226,000 |
| Free Cash Flow Prior Year | 46,056,000 |
Options |
|
| Put/Call Ratio | 0.33 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 4.37 |
| MACD Signal | 3.28 |
| 20-Day Bollinger Lower Band | 93.19 |
| 20-Day Bollinger Middle Band | 109.82 |
| 20-Day Bollinger Upper Band | 126.45 |
| Beta | 0.71 |
| RSI | 70.41 |
| 50-Day SMA | 109.61 |
| 150-Day SMA | 85.60 |
| 200-Day SMA | 93.04 |
System |
|
| Modified | 7/17/2025 4:02:31 AM EST |